Table 4.

Clinical, management and outcome characteristics of patients with GBM older and younger than 70 years

Characteristics	≤70 years, n (%) 642 (77.0)	>70 years, n (%) 192 (23.0)	P
Age (years)*	59 (20–70)	75 (71–85)	<.001
Sex
Male	407 63.4)	104 (54.2)	.023
Female	235 (36.6)	88 (45.8)
Symptoms
Focal	433 (67.6)	138 (71.9)	.290
Cognitive	222 (35.0)	91 (47.9)	.002
Epilepsy	161 (25.1)	44 (22.9)	.570
MRI location
Single lesion	534 (83.2)	166 (86.5)	.430
Lobara	417 (78.1)	138 (83.1)	.089
Right side	258 (48.3)	93 (56.0)	.051
Delay 1stimage-surgery (days)*	15 (0–177)	20 (0–152)	.002
Surgery
Gross total resection	257 (40.2)	56 (29.2)	<.001
Partial resection	188 (29.4)	48 (25)
Biopsy	194 (30.4)	88 (45.8)
Post-surgical complicationsb	78 (12.1)	37 (19.3)	.017
30- days mortality	44 (6.9)	22 (11.5)	.047
Postoperative KPS*	80 (100–10)	60 (100–10)	<.001
≥70	239 (69.2)	45 (44.2)
60	51 (14.8)	31 (30.4)
<60	55 (15.9)	26 (25.5)
1st line treatments
RT+ C plus A TMZ**	417 (65.0)	61 (31.8)	<.001
RT+ A TMZ***	26 (4.0)	5 (2.6)
RT+ BCNU wafers	16 (2.5)	7 (3.6)
RT alone	34 (5.3)	36 (18.8)
Clinical Trials	42 (6.5)	4 (2.1)
Palliative	107 (16.7)	79 (41.1)
No salvage treatment	175 (40.1)	59 (77.7)	<.001
OS in months (95%CI)	13.7 (12.6–14.8)	5.2 (4.3–6.1)	<.001
1 year SR	55.90%	24.50%
2 years SR	21.50%	10.10%

Abbreviations: C, concomitant; A, adjuvant; TMZ, temozolomide; OS, overall survival; SR, survival rate.

^aIsolate lobar lesion without corpus callosum and basal ganglia involvement.

^bOnly included major complication that significantly delayed or prevented oncological treatment.

*value expressed as median (range).

**43 patients also received BCNU wafers.

***10 patients also received BCNU wafers.